KLOWBlend
GHK-Cu + KPV + BPC-157 + TB-500 — the full glow stack.
- Status
- Research / not approved
- Developer
- Compounded research-peptide blend; vendor-specific
- Receptors / target
- Not a single target — combines GHK-Cu, KPV, BPC-157 and TB-500 (skin remodeling, anti-inflammatory, cytoprotective, and actin/angiogenic actions); no characterized combined pharmacology
- FDA-approved?
- NO
- Prescription available?
- NO
- Studied for
- tissue repairwound healinganti-inflammatory / gut inflammationskin rejuvenation / anti-agingrecovery (musculoskeletal, post-procedure)
Overview
KLOW is a compounded research-peptide blend combining four peptides — GHK-Cu, KPV, BPC-157 and TB-500 — in a single vial. It is essentially the three-component "GLOW" blend with KPV added (the "K" in KLOW), most commonly an ~80 mg vial in a 50/10/10/10 ratio, though component amounts vary by vendor. It is sold strictly for laboratory research; it is not an approved drug and has no clinical trials as a combination.
Mechanism
Each component acts through a distinct, individually-studied pathway rather than a unified mechanism. GHK-Cu is a copper-binding tripeptide associated with skin remodeling and repair-gene expression; KPV is an alpha-MSH-derived tripeptide with anti-inflammatory activity; and BPC-157 and TB-500 are studied for tissue-repair and angiogenic effects in preclinical models. The blend's rationale is that these complementary pathways may overlap in tissue repair and inflammation, but no published data characterize how the four behave together. Any synergy is hypothesized, not demonstrated.
Clinical evidence
There are no clinical trials of the KLOW blend — efficacy claims rest entirely on the individual components, much of it preclinical. KPV shows anti-inflammatory activity in cell and animal models; GHK-Cu has small human/topical skin data; and BPC-157 and TB-500 have animal/preclinical tissue-repair data with little to no controlled human evidence. No human trial has tested the four peptides combined, at these ratios, or by this route. Treat all blend-level benefit claims as unproven.
Safety profile
KLOW is research-use-only and not FDA-evaluated; the combined-injection safety of the four peptides is unstudied. Reported component-level effects are mostly anecdotal — injection-site reactions, flushing, fatigue, nausea, lightheadedness — and GHK-Cu adds theoretical copper concerns. TB-500 (thymosin beta-4) is on the WADA Prohibited List, so KLOW is banned in sport. Sterility, dosing and long-term safety of compounded multi-peptide vials are not established. Nothing here is therapeutic or dosing guidance.
- Weeks
No trials of the four-peptide blend; per-component evidence ranges from small-human (GHK-Cu) to preclinical/anecdotal (KPV, BPC-157, TB-500). TB-500 makes it WADA-prohibited. Any timeline is unverified.
Reported in published literature and user reports. Not a complete list, and not medical advice.
- Injection-site reactions (redness, swelling, pain)
- Flushing, fatigue, nausea, lightheadedness (anecdotal, component-level)
- Theoretical copper-related effects (GHK-Cu)
- Unstudied combined-injection safety
If severe or unexpected symptoms occur, contact a qualified medical professional. PEPTIDES·INDEX does not provide medical advice.
- No human safety data exist for the four-peptide blend; combined-injection safety is unstudied and research-use only.
- GHK-Cu carries copper; cumulative or high-dose use raises theoretical copper-overload concerns, especially in those with Wilson's disease or copper-metabolism disorders.
- BPC-157 and TB-500 are pro-angiogenic in preclinical models, raising a theoretical concern in the setting of active or prior malignancy.
- No documented human drug interactionsNo interaction studies of the combination; uncharacterized in humans (research use only)
Compare
- vs GLOW
The base three-peptide blend (GHK-Cu + BPC-157 + TB-500) without KPV.
- vs Wolverine
Related repair-oriented blend; compare component makeup and ratios.
- vs KPV
The single KPV component — the anti-inflammatory peptide that distinguishes KLOW from GLOW.
FAQ
Is the KLOW blend studied in clinical trials?
No. There are no clinical trials of the four-peptide KLOW combination. Evidence is per component only — much of it preclinical (KPV, BPC-157, TB-500) with small human/topical data for GHK-Cu — and any combined benefit is unproven.
What is in KLOW?
Four peptides in one vial — GHK-Cu, KPV, BPC-157 and TB-500. It is essentially the three-component GLOW blend with KPV added (the K in KLOW), most commonly an ~80 mg vial in a 50/10/10/10 ratio, though amounts vary by vendor.
Is KLOW banned in sport?
Yes. It contains TB-500 (thymosin beta-4), which is on the WADA Prohibited List at all times, so KLOW is prohibited in sport.
How does KLOW differ from GLOW?
KLOW is GLOW (GHK-Cu + BPC-157 + TB-500) with KPV added as a fourth peptide. KPV is the anti-inflammatory addition — an alpha-MSH-derived tripeptide — so KLOW layers an extra anti-inflammatory pathway on top of GLOW's repair components. Both are unstudied as blends and both contain WADA-prohibited TB-500.
What does the added KPV do?
KPV is the C-terminal tripeptide of alpha-MSH studied in cell and animal models for anti-inflammatory activity, including in intestinal inflammation. Its evidence is preclinical, it has no human interventional trials of its own, and how it behaves alongside the other three peptides in KLOW has not been characterized.
How is KLOW administered?
It is a compounded four-peptide vial reported to be reconstituted and injected subcutaneously. There is no validated dosing or route for the blend, and the combined-injection safety and sterility of compounded multi-peptide vials are not established. Research use only.
Related guides
ArticleGLOW vs KLOW: Which Peptide Blend Is Better? The KPV DifferenceSimilar compounds
Starting references for the library summary. These are not dosing instructions or medical advice.
For research-use educational context only. Not medical advice and not a recommendation to use any compound. Consult a qualified healthcare professional before any health decision.